

Contents

1 Summary and Policy Options 1


- Scope of the OTA Report 2
 - Tuberculosis, Health Care Reform, and Public Health Investments 2
 - What Is TB? 2
 - What Is the Risk of TB Infection? 3
 - Trends in the Incidence of Active TB 3
 - The Changing Demographics of TB 4
 - Multidrug-Resistant Tuberculosis 6
 - Three Strategies for TB Prevention 6
 - Diagnosis of Active TB 8
 - Treatment of Active TB 9
 - Delivering TB Treatment 10
 - Federal Involvement in TB Control 12
 - Policy Options for Congress 16

2 Etiology and Transmission of Tuberculosis 27

- Transmission and Infectivity 28
 - Factors Influencing the Probability of Acquiring Tuberculous Infection 28
 - Factors Influencing the Development of Active TB After Infection 30
- Development of Tuberculosis and Its Clinical Manifestations 30
 - Immune Responses to Tuberculous Infection and Disease 31
 - Clinical Course in HIV-Seropositive Individuals 32
 - Clinical Course in Children 32

3 The Changing Epidemiology of Tuberculosis 33

- Overall Trends in TB Incidence 33
- Demographic Changes *in* TB 34
 - Geographic Distribution 35
 - Race, Ethnicity, Age, and Sex 37
 - High-Risk Populations 40



HIV and AIDS: Epidemiologic Association With
TB 42
The Prevalence of TB Among Individuals With
MDs 43
Multidrug-Resistant Tuberculosis 44
Recent Outbreaks of MDR-TB in Institutional
Settings 46
Factors Underlying the TB Resurgence in the
United States 47

4 Strategies to Prevent Tuberculous Infection and Active Disease 49

Infection Control 50
Infection Control Measures 52
Tuberculin Skin Testing and Preventive
Treatment 55
Identifying Individuals with Tuberculous
Infection 59
Isoniazid Preventive Treatment 61
BCG Vaccination 62
The Nature and Rationale for BCG Vaccines 63
Efficacy and Safety of BCG Vaccination 64
Impact of BCG Vaccination on the Incidence of
TB 65
BCG Vaccination Policy in the United States 66
Issues Concerning Future Use of Vaccination
Against TB 67

5 Diagnosis and Treatment of Active TB 69

Diagnosis of TB and Resistance to Anti-TB Drugs 70
Treatment of Active TB 72
Rationale for Antimicrobial Treatment of TB 74
Current Treatment Regimens 75
Treatment of TB in Individuals with AIDS 76
Treatment of Multidrug-Resistant TB 76
New Approaches to Treatment 78
The Cost of Drugs for Tuberculosis Treatment 79

6 Delivery of Treatment for Tuberculosis 81

Magnitude of the Problem 82
Factors Involved in Treatment Outcome 84
Provision of TB Control Services 84
Medical Care Practices 86
Patient Behavior 87
Available Strategies for Improving Treatment
Delivery 88

7 Federal Involvement in Tuberculosis Control and Research 91

- Public Health Activities 92
 - The Centers for Disease Control and Prevention 92
 - Occupational Health and Safety Administration 97
 - U.S. Departments of Justice and State 98
 - U.S. Department of Veterans Affairs 98
 - Indian Health Service 99
 - Federal Bureau of Prisons 99
 - U.S. Agency for International Development 99
 - Health Resources and Services Administration 100
- Research and Development 100
 - National Institutes of Health 100
- Regulation of Technologies 102
- Health Services Research 102
- Housing 103
- Reimbursement for TB Services 103
 - Disability Programs Administered by the Social Security Administration 103
 - The Role of Federal Health Insurance Programs 103

APPENDIXES

- A Acknowledgments 107**
- B Abbreviations and Glossary 112**

REFERENCES 119

INDEX 141